Project description:4 replicates were prepared from A2058 melanoma cells [transfected with 10ng of empty vector (pcDNA3.1+)] and treated with 5ng/ml TGFβ1 or vehicle control for 24hrs
Project description:4 replicates were prepared from A2058 melanoma cells [transfected with 10ng of empty vector (pcDNA3.1+)] and treated with 5ng/ml TGFβ1 or vehicle control for 24hrs This is the control arm of a larger experiment where cells transfected with a particular expression plasmid were treated with TGFβ1 or control vehicle. The transfection with the expresion plasmid was unsucessful so this empty vector data has been used alone to simply examine the effect of TGFβ1 treatment on A2058 cells.
Project description:We performed bulk RNA-seq on cultured melanoma with up- and down- regulation of the master regulator MITF in A2058 human melanoma cells.
Project description:Human melanoma A2058 cells were transfected with PARP1 siRNA or control siRNA for 48 and 72 h. Goal was to determine the effects of PARP1 on global A2058 gene expression by comparing the changes in the expression profile of melanoma cells after PARP1 interference.
Project description:The cellular gene expression profiles were investigated after CT16 (PAGE5) silencing in CT16 positive A2058 melanoma cells. Control siRNA treated A2058 cells was used as a negative control. Total RNA from three individual cultures of A2058 cells treated with CT16 siRNA and from three individual cultures of A2058 cells treated with control siRNA.
Project description:Human melanoma cell line A375 and A2058 were incubated with DMSO (control group) or Vemurafenib (1 μM in DMSO) for 72 hours. Total RNA was isolated with Qiagen RNA isolation kit; 1.5 μg of total RNA was used as template for cDNA synthesis.
Project description:The cellular gene expression profiles were investigated after CT16 (PAGE5) silencing in CT16 positive A2058 melanoma cells. Control siRNA treated A2058 cells was used as a negative control.
Project description:The goal of this study was to unlock the cellular diversity of A2058, a melanoma cell line known to be resistant to BRAF inhibition, by performing single cell RNAseq profiling using a 10X genomics platform. This approach allowed us to study the transcriptional programming of every single melanoma cell, particularly of those cells expressing ABCB5, a cell surface protein involved in invasiveness and resistance to BRAF inhibition. Findings from this study revelaed that ABCB5-expressing cells also expressed melanocytic genes (MITF) but with a distinct transcriptional program to those expressing AXL. We also used this data to identify the expresion of commonly studied drug efflux pumps in melanoma cells.
Project description:This SuperSeries is composed of the following subset Series: GSE31350: Transcriptomic analysis of the effect of CT16 (PAGE5) expression in WM-266-4 melanoma cells GSE31351: Transcriptomic analysis of the effect of CT16 (PAGE5) silencing by RNAi in A2058 melanoma cells Refer to individual Series
Project description:This study investigates the transcriptional consequences of loss of the Mas-related G protein?coupled receptor MRGPRX4 in human melanoma cells. Bulk RNA sequencing was performed on CRISPR-Cas9-engineered MRGPRX4 knockout and control A2058 melanoma cell lines. Sequencing data were processed using established RNA-seq workflows, including quality control and transcript quantification, followed by differential gene expression and functional enrichment analyses to identify gene expression programs regulated by MRGPRX4.